Previous close | 26.30 |
Open | 26.30 |
Bid | 5.50 |
Ask | 12.10 |
Strike | 930.00 |
Expiry date | 2025-01-17 |
Day's range | 26.30 - 26.30 |
Contract range | N/A |
Volume | |
Open interest | 62 |
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
HRMY vs. REGN: Which Stock Is the Better Value Option?